J. Durant

Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial

J. Durant, Philippe Clevenbergh, Philippe Halfon et al. · The Lancet · 1999 · 761 citations

Health Sciences, Treatment And Prevention, Human Retrovirus +11

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

Antonella Castagna, Franco Maggiolo, Giovanni Penco et al. · The Journal of Infectious Diseases · 2014 · 322 citations · Full text

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

Joseph J. Eron, Bonaventura Clotet, J. Durant et al. · The Journal of Infectious Diseases · 2012 · 306 citations · Full text

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study

J. Durant, Philippe Clevenbergh, R. Garraffo et al. · AIDS · 2000 · 223 citations

Is Intrapartum Intravenous Zidovudine for Prevention of Mother-to-Child HIV-1 Transmission Still Useful in the Combination Antiretroviral Therapy Era?

Nelly Briand, Josiane Warszawski, Laurent Mandelbrot et al. · Clinical Infectious Diseases · 2013 · 126 citations · Full text